8-K: QHSLab Reports Strong 2025 Revenue Growth, Debt Reduction

QHSLab Inc. announced preliminary unaudited 2025 financial results, showcasing over 25% revenue growth, expanded gross margins, and significant convertible debt reduction.

Summary

• Revenue for the year ended December 31, 2025, increased just over 25% to $2,676,074, compared to $2,131,926 in 2024.
• Gross profit for 2025 was $1,795,182, representing growth of more than 32% year over year from $1,357,890 in 2024.
• Gross profit margin expanded meaningfully in 2025, increasing from approximately 64% in 2024 to approximately 67% in 2025.
• Outstanding convertible debt and associated accrued interest were reduced from approximately $2.0 million to approximately $20,000 during Q4 2025.
• Annual interest expense is expected to decline by more than $200,000 on a forward-looking basis.
• The Q-Cog pilot program began generating reimbursement activity following its initial deployment phase in December 2025.

Sentiment

Score: 8

Explanation: The filing reports strong preliminary financial results including significant revenue and gross profit growth, expanded margins, and a substantial reduction in convertible debt. The positive outlook for Q-Cog and expected interest expense savings contribute to a very positive sentiment, despite the unaudited nature of the results.

Positives

• Strong revenue growth of over 25% year-over-year, reaching $2,676,074 in 2025.
• Significant gross profit growth of over 32% year-over-year, totaling $1,795,182 in 2025.
• Meaningful expansion of gross profit margin from approximately 64% in 2024 to approximately 67% in 2025.
• Substantial reduction of outstanding convertible debt and accrued interest from approximately $2.0 million to approximately $20,000.
• Expected annual interest expense savings of over $200,000, improving cash flow and providing reinvestment flexibility.
• Early positive results and reimbursement activity from the Q-Cog pilot program, expected to be a meaningful incremental revenue stream in 2026.
• Strengthened balance sheet and capital structure through debt restructuring and extinguishment.

Negatives

• The reported financial results are preliminary and unaudited, subject to adjustment as the Company completes its year-end financial close process.
• The company operated with limited resources and focused on addressing historical obligations during the reported year.

Risks

• Preliminary unaudited financial results are subject to adjustment during the year-end financial close process.
• Forward-looking statements are subject to numerous risks and uncertainties, including the timing of new product introductions, availability of financing, discrepancies in actual results from estimates, regulatory delays, changes in government funding and budgets, and general economic conditions.
• The company operated with limited resources during the reported period.

Future Outlook

QHSLab anticipates continued platform expansion in 2026, driven by improved profitability and early Q-Cog reimbursement activity. Management expects Q-Cog to become a meaningful incremental revenue stream in 2026. The company believes the combination of accelerating revenue growth, expanding margins, a substantially de-risked balance sheet, and new reimbursable solutions positions it well for continued progress in 2026.

Management Comments

• "Our 2025 results reflect the resilience of our business model and the commitment of our team. Even while operating with limited resources and addressing historical obligations, we delivered strong revenue growth, improved profitability, and materially strengthened our financial position for the years ahead." Troy Grogan, President and CEO of QHSLab, Inc.

Industry Context

QHSLab operates in the digital health infrastructure sector, providing preventive screening, assessment, and workflow solutions for primary care practices. The Q-Cog solution addresses a significant unmet need for early cognitive screening tools at the primary-care level, aligning with CMS screening guidelines, Annual Wellness Visit requirements, and supporting neurocognitive and behavioral health CPT codes. This positions the company to capitalize on the growing demand for scalable, reimbursable digital medicine platforms and value-based care models.

Stakeholder Impact

• Shareholders: Benefit from strengthened financial position, reduced debt, improved profitability, and potential for future growth and increased shareholder value. The conversion of debt holders to stockholders reflects confidence.
• Creditors: Convertible debt holders have converted to equity, significantly reducing the company's debt obligations.
• Employees: Continued operational momentum and platform expansion may lead to stability and growth opportunities.
• Customers (Primary Care Practices): Benefit from continued development and expansion of digital health solutions like Q-Cog, addressing unmet needs and supporting compliance.

Next Steps

• Complete the year-end financial close process for 2025.
• File the Annual Report on Form 10-K with the SEC before the end of March 2026, including final audited financial results.
• Continue platform expansion in 2026.
• Further develop and expand the Q-Cog solution to become a meaningful incremental revenue stream in 2026.
• Reinvest in product development, sales execution, and platform expansion.

Key Dates

Recommendation

The company reported substantial revenue growth (25%), significant gross profit expansion (32%), and a meaningful increase in gross profit margin (from 64% to 67%). Crucially, QHSLab nearly eliminated its convertible debt, reducing it from $2.0 million to $20,000, which is expected to save over $200,000 in annual interest expense. The early success of the Q-Cog pilot program, with anticipated incremental revenue in 2026, further strengthens the growth trajectory. These factors collectively indicate a materially improved financial position and strong operational momentum, making the stock an attractive investment.

Keywords

QHSLab, USAQ, Financial Results, Revenue Growth, Gross Margin, Debt Reduction, Digital Health, Healthcare Technology, Q-Cog, Preliminary Results, SEC Filing